Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia

Drugs of Today

Volumn 43, Issue SUPPL. A, 2007, Pages 1-10

  Momose, Hitoshi ^a   Hosokawa, Yukinari ^a   Kishino, Tatsuki ^a   Ono, Takamasa ^a   Oyama, Nobuo ^a  

^a HOSHIGAOKA KOSEINENKIN HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NAFTOPIDIL; TAMSULOSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; IMPAIRED BLADDER EMPTYING; LOWER URINARY TRACT SYMPTOM; MALE; MICTURITION DISORDER; NOCTURIA; ORTHOSTATIC HYPOTENSION; POLLAKISURIA; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PIPERAZINES; PROSTATIC HYPERPLASIA; SULFONAMIDES; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 33947509519     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Homma, Y., Kawabe, K., Tsukamoto, T. et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. Int J Urol 1997, 4: 40-6.
2. Roberts, R.O., Jacobsen, S.J., Rhodes, T. et al. Natural history of prostatism: Impaired health states in men with lower urinary tract symptoms. J Uro 1997, 157: 1711-7.
3. Girman, C.J., Jacobsen, S.J., Tsukamoto, T. et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998, 51: 428-36.
4. Sarma, A.V., Jacobsen, S.J., Girman, C.J. et al. Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. J Uro 2002, 168: 1446-52.
5. Research Group for Standardization of Treatments of Urology Disorders (Eds.). Guideline for EBM-based Treatment of Benign Prostatic Hyperplasia. Jiho, Inc.: Tokyo 2001.
6. Guideline on the Management of Benign Prostatic Hyperplasia. American Urological Association 2003.
7. Guidelines on Benign Prostatic Hyperplasia. European Association of Urology 2004.
8. Lowe, F. Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1999, 2: 110-9.
9. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999, 36: 1-13.
10. Clifford, G.M., Farmer, R.D. Medical therapy for benign prostatic hyperplasia: A review of the literature. Eur Urol 2000, 38: 2-19.
11. Logie, J.W., Clifford, G.M., Farmer, R.D., Meesen, B.P. Lower urinary tract symptoms suggestive of benign prostatic obstruction - Triumph: The role of general practice databases. Eur Urol 2001, 39 (Suppl. 3): 42-7.
12. 1-adrenoceptor antagonists. BJU Int 2005, 95 (Suppl. 4): 29-36.
13. Gotoh, M., Kamihira, O., Kinukawa, T. et al.; Tokai Urological Clinical Trial Group. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: A randomized controlled trial. BJU Int 2005, 96: 581-6.
14. 1-adrenoceptor subtype mRNAs in human prostate: Comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 1996, 119: 797-803.
15. Kojima, Y., Sasaki, S., Kohri, K., Shinoura, H., Tsujimoto, G. Correlation between alpha1-adrenoceptor subtype mRNA expression level and efficacy of naftopidil for BPH patients. Neurourol Urodyn 2004, 23: 467-8.
16. 1-adrenergic receptor subtypes in human detrusor. J Urol 1998, 160: 937-43.
17. 1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 2002, 167: 1513-21.
18. 1-adrenoceptors. Jpn J Pharmacol 1999, 79: 447-54.
19. Ikemoto, I., Kiyota, H., Ohishi, Y. et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: A comparative, randomized, two-drug crossover study. Int J Urol 2003, 10: 587-94.
20. 1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: A randomized crossover study. BJU Int 2006, 97: 747-51.
21. Sugaya, K., Nishijima, S., Miyazato, M. et al. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci Lett 2002, 328: 74-6.
22. 1-adrenergic receptor subtypes at four distinct levels. Mol Brain Res 1999, 63: 254-61.
23. Yokoyama, O., Nagano, K., Kawaguchi, K., Ueki, O., Ohkawa, M. The influence of prostatic urethral anesthesia in overactive detrusor in patients with benign prostatic hyperplasia. J Urol 1994, 151: 1554-6.
24. Yokoyama, O., Yusuf, A., Tanase, K. et al. Effect of tamsulosin on rat overactive bladder mediated by c-fibers in lower urinary tract. Jpn J Urol 2005, 96: 225 (Abstr. OP2-012).
25. Narayan, P., Evans, C.P., Moon, T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003, 170: 498-502.
26. 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997, 80: 587-96.
27. 1C-adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol 1995, 76: 325-36.